Download PDF

1. Company Snapshot

1.a. Company Description

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally.The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products.It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu.


The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems.It also exports its products.Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.

Show Full description

1.b. Last Insights on FAE

Faes Farma's recent performance was driven by a favorable European market backdrop, with the STOXX Europe 600 Index climbing 3.93% over a recent week. The company's resilience in a mixed global market environment is attributed to its strong fundamentals and potential for growth. Additionally, the European market's modest recovery, with the STOXX Europe 600 Index rising by 0.56%, has created a conducive environment for dividend stocks, of which Faes Farma is a part. Furthermore, the company's recent news and earnings release have not been publicly disclosed, but it is worth noting that the European market's focus on resilient opportunities has led to increased interest in stocks with strong fundamentals, such as Faes Farma.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

3 European Dividend Stocks Yielding Up To 9.3%

Nov -17

Source:

Card image cap

European Penny Stocks To Consider In November 2025

Nov -11

Source:

Card image cap

European Penny Stocks To Watch In November 2025

Nov -06

Source:

Card image cap

European Penny Stocks To Watch In November 2025

Nov -06

Source:

Card image cap

Binero Group And 2 Other European Penny Stocks To Consider For Your Watchlist

Nov -05

Source:

Card image cap

November 2025's European Penny Stocks Worth Watching

Nov -05

Source:

Card image cap

European Penny Stocks To Consider In November 2025

Nov -04

Source:

Card image cap

European Penny Stocks To Watch In November 2025

Nov -04

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (1.15%)

6. Segments

Pharmaceutical Specialties and Healthcare

Expected Growth: 1.2%

Faes Farma's 1.2% growth in Pharmaceutical Specialties and Healthcare is driven by increasing demand for chronic disease treatments, an aging population, and strategic partnerships. Additionally, the company's focus on R&D, expansion into emerging markets, and cost-saving initiatives contribute to its growth momentum.

Nutrition and Animal Health

Expected Growth: 0.8%

Faes Farma's Nutrition and Animal Health segment growth of 0.8 is driven by increasing demand for animal feed additives, expansion into emerging markets, and strategic partnerships. Additionally, growing consumer awareness of animal welfare and sustainable farming practices contribute to the segment's growth.

Others

Expected Growth: 0.5%

Faes Farma's 0.5 growth is driven by increasing demand for its pharmaceutical products, particularly in the allergy treatment segment. Strong brand recognition, strategic partnerships, and efficient supply chain management also contribute to its growth. Additionally, the company's focus on R&D and innovation enables it to stay competitive in the market.

7. Detailed Products

Fluoxetine

An antidepressant medication used to treat depression, obsessive-compulsive disorder, and some eating disorders.

Omeprazole

A medication used to treat gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome.

Ranitidine

A medication used to treat gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other conditions caused by excess stomach acid.

Ciprofloxacin

An antibiotic used to treat bacterial infections, including urinary tract infections, pneumonia, and anthrax.

Doxycycline

An antibiotic used to treat bacterial infections, including pneumonia, acne, and Lyme disease.

Ibuprofen

A nonsteroidal anti-inflammatory drug (NSAID) used to treat pain, reduce inflammation, and lower fever.

8. Faes Farma, S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Faes Farma, S.A. faces moderate threat from substitutes due to the presence of alternative pharmaceutical products in the market.

Bargaining Power Of Customers

Faes Farma, S.A. has a diverse customer base, which reduces the bargaining power of individual customers.

Bargaining Power Of Suppliers

Faes Farma, S.A. relies on a few key suppliers for raw materials, which gives them some bargaining power.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, but new entrants can still pose a threat to Faes Farma, S.A. due to advancements in technology and changing regulatory environments.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, and Faes Farma, S.A. faces intense rivalry from established players and new entrants.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 3.48%
Debt Cost 3.95%
Equity Weight 96.52%
Equity Cost 6.31%
WACC 6.23%
Leverage 3.61%

11. Quality Control: Faes Farma, S.A. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Faes Farma

A-Score: 7.4/10

Value: 5.2

Growth: 5.9

Quality: 8.2

Yield: 8.1

Momentum: 8.0

Volatility: 9.0

1-Year Total Return ->

View Full Report
Stock-Card
Fagron

A-Score: 5.6/10

Value: 4.5

Growth: 5.0

Quality: 6.1

Yield: 1.9

Momentum: 6.5

Volatility: 9.3

1-Year Total Return ->

View Full Report
Stock-Card
Reig Jofre

A-Score: 5.3/10

Value: 6.8

Growth: 7.9

Quality: 5.1

Yield: 1.9

Momentum: 4.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Vetoquinol

A-Score: 4.5/10

Value: 5.6

Growth: 4.8

Quality: 7.0

Yield: 1.2

Momentum: 3.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Boiron

A-Score: 4.5/10

Value: 5.7

Growth: 2.1

Quality: 6.2

Yield: 8.8

Momentum: 1.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Swedencare

A-Score: 3.5/10

Value: 3.1

Growth: 8.9

Quality: 4.7

Yield: 0.6

Momentum: 2.0

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

4.67$

Current Price

4.67$

Potential

-0.00%

Expected Cash-Flows